
## Gretchen M Brophy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4669258/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predicting Clinical Outcomes 7–10 Years after Severe Traumatic Brain Injury: Exploring the Prognostic Utility of the IMPACT Lab Model and Cerebrospinal Fluid UCH-L1 and MAP-2. Neurocritical Care, 2022, , .	1.2	0
2	Time Is Brain: Acute Control of Repetitive Seizures and Status Epilepticus Using Alternative Routes of Administration of Benzodiazepines. Journal of Clinical Medicine, 2021, 10, 1754.	1.0	14
3	Intravenous Versus Oral Acetaminophen Use in Febrile Neurocritical Care Patients. Therapeutic Hypothermia and Temperature Management, 2021, , .	0.3	0
4	High-Dose Intravenous Ascorbic Acid: Ready for Prime Time in Traumatic Brain Injury?. Neurocritical Care, 2020, 32, 333-339.	1.2	7
5	Principles of Pharmacotherapy of Seizures and Status Epilepticus. Seminars in Neurology, 2020, 40, 681-695.	0.5	2
6	Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants. Current Opinion in Critical Care, 2020, 26, 122-128.	1.6	6
7	Prevention, Treatment, and Monitoring of Seizures in the Intensive Care Unit. Journal of Clinical Medicine, 2019, 8, 1177.	1.0	16
8	Targeted Temperature Management in Nursing Care. Therapeutic Hypothermia and Temperature Management, 2019, 9, 173-176.	0.3	0
9	Unique Uses of Cooling Strategies. Therapeutic Hypothermia and Temperature Management, 2019, 9, 168-172.	0.3	1
10	Common Data Elements for Unruptured Intracranial Aneurysms and Aneurysmal Subarachnoid Hemorrhage: Recommendations from the Working Group on Hospital Course and Acute Therapies—Proposal of a Multidisciplinary Research Group. Neurocritical Care, 2019, 30, 36-45.	1.2	18
11	Sedation in theÂCritical Care Unit. , 2019, , 299-318.		1
12	Metabolomics and Precision Medicine in Trauma: The State of the Field. Shock, 2018, 50, 5-13.	1.0	18
13	Temporal Profile of Microtubule-Associated Protein 2: A Novel Indicator of Diffuse Brain Injury Severity and Early Mortality after Brain Trauma. Journal of Neurotrauma, 2018, 35, 32-40.	1.7	19
14	Treatment of Hyponatremia in Patients with Acute Neurological Injury. Neurocritical Care, 2017, 27, 242-248.	1.2	20
15	Pharmacotherapy Pearls for Emergency Neurological Life Support. Neurocritical Care, 2017, 27, 51-73.	1.2	25
16	What's new in refractory status epilepticus?. Intensive Care Medicine, 2017, 43, 543-546.	3.9	19
17	Medical management of epileptic seizures: challenges and solutions. Neuropsychiatric Disease and Treatment, 2016, 12, 467.	1.0	24
18	Managing Status Epilepticus in the Older Adult. Journal of Clinical Medicine, 2016, 5, 53.	1.0	17

**GRETCHEN M BROPHY** 

#	Article	IF	CITATIONS
19	Clinical Q & A: Translating Therapeutic Temperature Management from Theory to Practice. Therapeutic Hypothermia and Temperature Management, 2016, 6, 146-149.	0.3	0
20	Intravenous Versus Oral Acetaminophen for Pain Control in Neurocritical Care Patients. Neurocritical Care, 2016, 25, 400-406.	1.2	8
21	Clinical Q & A: Translating Therapeutic Temperature Management from Theory to Practice. Therapeutic Hypothermia and Temperature Management, 2016, 6, 218-222.	0.3	Ο
22	Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury. JAMA Neurology, 2016, 73, 551.	4.5	348
23	Emergency Neurological Life Support: Pharmacotherapy. Neurocritical Care, 2015, 23, 48-68.	1.2	21
24	Treatment of Super-Refractory Status Epilepticus. Current Neurology and Neuroscience Reports, 2015, 15, 66.	2.0	36
25	Biomarkers Improve Clinical Outcome Predictors of Mortality Following Non-Penetrating Severe Traumatic Brain Injury. Neurocritical Care, 2015, 22, 52-64.	1.2	50
26	The International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: Evidentiary Tables. Neurocritical Care, 2014, 21, 297-361.	1.2	80
27	Response to "Modifications to the Drug Burden Index Calculation May Limit Interpretation of Its Association With Clinical Outcomes In Older Adultsâ€(doi:10.1007/s12028-014-0006-8). Neurocritical Care, 2014, 21, 367-368.	1.2	0
28	GFAP Out-Performs S100β in Detecting Traumatic Intracranial Lesions on Computed Tomography in Trauma Patients with Mild Traumatic Brain Injury and Those with Extracranial Lesions. Journal of Neurotrauma, 2014, 31, 1815-1822.	1.7	163
29	The International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: A List of Recommendations and Additional Conclusions. Neurocritical Care, 2014, 21, 282-296.	1.2	71
30	Consensus Summary Statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care. Neurocritical Care, 2014, 21, 1-26.	1.2	339
31	Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care. Intensive Care Medicine, 2014, 40, 1189-1209.	3.9	258
32	Potentially Inappropriate Medication Use is Associated with Clinical Outcomes in Critically III Elderly Patients with Neurological Injury. Neurocritical Care, 2014, 21, 526-533.	1.2	18
33	Adverse Neurologic Effects of Medications Commonly Used in the Intensive Care Unit. Critical Care Clinics, 2014, 30, 795-811.	1.0	7
34	Treatment of Status Epilepticus: An International Survey of Experts. Neurocritical Care, 2013, 18, 193-200.	1.2	88
35	Exposure of Cyclosporin A in Whole Blood, Cerebral Spinal Fluid, and Brain Extracellular Fluid Dialysate in Adults with Traumatic Brain Injury. Journal of Neurotrauma, 2013, 30, 1484-1489.	1.7	20
36	Thalamic and Subthalamic Deep Brain Stimulation for Essential Tremor. Neurosurgery, 2012, 70, 840-846.	0.6	264

#	Article	IF	CITATIONS
37	Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. Journal of Trauma, 2012, 72, 1335-1344.	2.3	196
38	Perceived Versus Actual Sedation Practices in Adult Intensive Care Unit Patients Receiving Mechanical Ventilation. Annals of Pharmacotherapy, 2012, 46, 1331-1339.	0.9	50
39	Guidelines for the Evaluation and Management of Status Epilepticus. Neurocritical Care, 2012, 17, 3-23.	1.2	1,296
40	Elevated Levels of Serum Clial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention. Annals of Emergency Medicine, 2012, 59, 471-483.	0.3	282
41	Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient Biofluids. Journal of Neurotrauma, 2011, 28, 861-870.	1.7	205
42	Management of Intracranial Hypertension: Focus on Pharmacologic Strategies. AACN Advanced Critical Care, 2011, 22, 177-182.	0.6	3
43	Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury*. Critical Care Medicine, 2010, 38, 138-144.	0.4	259
44	Prospective, Randomized Comparison of Lansoprazole Suspension, and Intermittent Intravenous Famotidine on Gastric pH and Acid Production in Critically ill Neurosurgical Patients. Neurocritical Care, 2010, 13, 176-181.	1.2	24
45	Pharmacological Management of Seizures and Status Epilepticus in Critically III Patients. Journal of Pharmacy Practice, 2010, 23, 441-454.	0.5	17
46	αII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients. Journal of Neurotrauma, 2010, 27, 1203-1213.	1.7	193
47	αII-Spectrin Breakdown Product Cerebrospinal Fluid Exposure Metrics Suggest Differences in Cellular Injury Mechanisms after Severe Traumatic Brain Injury. Journal of Neurotrauma, 2009, 26, 471-479.	1.7	122
48	Safety of Imipenem/Cilastatin in Neurocritical Care Patients. Neurocritical Care, 2009, 10, 403-407.	1.2	20
49	Symptomatic Venous Thromboembolism: Incidence and Risk Factors in Patients with Spontaneous or Traumatic Intracranial Hemorrhage. Neurocritical Care, 2009, 11, 28-33.	1.2	71
50	Safety and Tolerability of Cyclosporin A in Severe Traumatic Brain Injury Patients: Results from a Prospective Randomized Trial. Journal of Neurotrauma, 2009, 26, 2195-2206.	1.7	98
51	A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit. Clinical Therapeutics, 2008, 30, 2324-2334.	1.1	8
52	Use of biomarkers for diagnosis and management of traumatic brain injury patients. Expert Opinion on Medical Diagnostics, 2008, 2, 937-945.	1.6	56
53	Clinical Significance ofαII-Spectrin Breakdown Products in Cerebrospinal Fluid after Severe Traumatic Brain Injury. Journal of Neurotrauma, 2007, 24, 354-366.	1.7	194
54	Quantification of Cyclosporin A in Human Cerebrospinal Fluid by Liquid Chromatographyâ€Mass Spectrometry using Atmospheric Pressure Chemical Ionization. Journal of Liquid Chromatography and Related Technologies, 2007, 30, 1733-1747.	0.5	6

#	Article	IF	CITATIONS
55	Comparison of Darbepoetin alfa and Epoetin alfa in the Management of Anemia of Critical Illness. Pharmacotherapy, 2007, 27, 535-541.	1.2	8
56	The Richmond Agitation–Sedation Scale. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1338-1344.	2.5	2,873
57	Pharmacist Impact on Posttraumatic Seizure Prophylaxis in Patients with Head Injury. Pharmacotherapy, 2002, 22, 251-255.	1.2	17
58	Multidisciplinary Management of Sedation and Analgesia in Critical Care. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 211-226.	0.8	116